Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04381832
Title Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer (ARC-6)
Recruitment Recruiting
Gender male
Phase Phase Ib/II
Variant Requirements No
Sponsors Arcus Biosciences, Inc.
Indications

prostate cancer

Therapies

AB928 + Enzalutamide + Zimberelimab

AB928 + Docetaxel + Zimberelimab

AB680 + AB928 + Zimberelimab

AB680 + AB928

Enzalutamide

Docetaxel

AB928 + Zimberelimab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.